Detect SARS-CoV-2 and 3 other pathogens with one NeuMoDx test.
As COVID-19 continues to affect our everyday lives, it becomes more critical for patients to know if they are infected with SARS-CoV-2 or a different pathogen.
Critical decisions for patient care are dependent on accurate and timely clinical laboratory results. To meet this demand, your lab needs full automation, faster turnaround times, scalability, and streamlined workflows. NeuMoDx systems address these needs – and more.
Connect with a specialist to learn more about NeuMoDx or set up a demo for your lab.
Product availability may vary by country specific regulatory requirements and approvals. Contact your country representative for further details.
The NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage Assay is intended for in vitro diagnostic use.
In the United States:
Your NeuMoDx team